Disclosures for "GLP-1 Receptor Agonist Use Associated With Greater Physical Activity and Improved Patient-reported Outcomes in Multiple Sclerosis: A Single-site Retrospective Cohort Study"
-
Dr. Heward has nothing to disclose.
-
Dr. Hou has nothing to disclose.
-
The institution of Dr. Simmons has received research support from National Multiple Sclerosis Society.
-
Dr. Kim has nothing to disclose.
-
Dr. Persenaire has nothing to disclose.
-
The institution of Dr. Madill has received research support from American Academy of Neurology.
-
Dr. Wang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Wang has received research support from Genentech. The institution of Dr. Wang has received research support from uniQure. The institution of Dr. Wang has received research support from NIH/NINDS.
-
The institution of Dr. Von Geldern has received research support from Novartis. The institution of Dr. Von Geldern has received research support from Contineum Therapeutics. Dr. Von Geldern has received personal compensation in the range of $0-$499 for serving as a DSMB member with NIH, NINDS. Dr. Von Geldern has a non-compensated relationship as a editorial board member with MS and Related Disorders Journal that is relevant to AAN interests or activities.
-
The institution of Dr. Wundes has received research support from Benaroya Research Institute .
-
Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Roy has received research support from The Siegel Rare Neuroimmune Association.